InsiderTrades.com logo
When it comes to NVDA… “acceleration cycles” are the key
From DTI   |   Ad
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Use this link to see Nvidia Unchained right away!
Robert C. Goeltz II net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Robert Goeltz II Biography and Net Worth

CFO of Arcus Biosciences

Robert C. Goeltz occupies the position of Chief Financial & Accounting Officer of Arcus Biosciences, Inc.

In the past he occupied the position of Chief Financial Officer & Senior Vice President for CytomX Therapeutics, Inc., Chief Financial Officer of Unity Biotechnology, Inc., Finance Director of Tularik, Inc. and Chief Financial Officer at Onyx Pharmaceuticals, Inc.

Robert C. Goeltz received an MBA from UCLA Anderson School of Management and an undergraduate degree from Goizueta Business School-Emory.

What is Robert C. Goeltz II's net worth?

The estimated net worth of Robert C. Goeltz II is at least $746,366.40 as of January 2nd, 2024. Mr. Goeltz II owns 51,831 shares of Arcus Biosciences stock worth more than $746,366 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Goeltz II may own. Additionally, Mr. Goeltz II receives a salary of $745,290.00 as CFO at Arcus Biosciences. Learn More about Robert C. Goeltz II's net worth.

How old is Robert C. Goeltz II?

Mr. Goeltz II is currently 51 years old. There are 6 older executives and no younger executives at Arcus Biosciences. The oldest executive at Arcus Biosciences is Dr. Juan Carlos Jaen Ph.D., Co- Founder & President, who is 66 years old. Learn More on Robert C. Goeltz II's age.

What is Robert C. Goeltz II's salary?

As the CFO of Arcus Biosciences, Inc., Mr. Goeltz II earns $745,290.00 per year. There are 3 executives that earn more than Mr. Goeltz II. The highest earning executive at Arcus Biosciences is Dr. Juan Carlos Jaen Ph.D., Co- Founder & President, who commands a salary of $931,140.00 per year. Learn More on Robert C. Goeltz II's salary.

How do I contact Robert C. Goeltz II?

The corporate mailing address for Mr. Goeltz II and other Arcus Biosciences executives is 3928 Point Eden Way, Hayward CA, 94545. Arcus Biosciences can also be reached via phone at (510) 694-6200 and via email at [email protected]. Learn More on Robert C. Goeltz II's contact information.

Has Robert C. Goeltz II been buying or selling shares of Arcus Biosciences?

Robert C. Goeltz II has not been actively trading shares of Arcus Biosciences over the course of the past ninety days. Most recently, Robert C. Goeltz II sold 2,004 shares of the business's stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $20.00, for a transaction totalling $40,080.00. Following the completion of the sale, the chief financial officer now directly owns 51,831 shares of the company's stock, valued at $1,036,620. Learn More on Robert C. Goeltz II's trading history.

Who are Arcus Biosciences' active insiders?

Arcus Biosciences' insider roster includes Robert Goeltz II (CFO), Juan Jaen (President), Jennifer Jarrett (COO), Terry Rosen (CEO), and Carolyn Tang (General Counsel). Learn More on Arcus Biosciences' active insiders.

Are insiders buying or selling shares of Arcus Biosciences?

During the last twelve months, Arcus Biosciences insiders bought shares 1 times. They purchased a total of 15,238,095 shares worth more than $319,999,995.00. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 83,955 shares worth more than $1,577,199.69. The most recent insider tranaction occured on March, 27th when COO Jennifer Jarrett sold 11,551 shares worth more than $202,720.05. Insiders at Arcus Biosciences own 12.3% of the company. Learn More about insider trades at Arcus Biosciences.

Information on this page was last updated on 3/27/2024.

Robert C. Goeltz II Insider Trading History at Arcus Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2024Sell2,004$20.00$40,080.0051,831View SEC Filing Icon  
12/16/2022Sell2,453$30.75$75,429.7511,566View SEC Filing Icon  
12/16/2021Sell485$39.83$19,317.55View SEC Filing Icon  
9/9/2020Buy5,000$21.57$107,850.005,000View SEC Filing Icon  
See Full Table

Robert C. Goeltz II Buying and Selling Activity at Arcus Biosciences

This chart shows Robert C Goeltz II's buying and selling at Arcus Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arcus Biosciences Company Overview

Arcus Biosciences logo
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Read More

Today's Range

Now: $14.40
Low: $14.17
High: $14.71

50 Day Range

MA: $16.49
Low: $14.44
High: $18.44

2 Week Range

Now: $14.40
Low: $13.49
High: $20.31

Volume

273,973 shs

Average Volume

731,130 shs

Market Capitalization

$1.32 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89
When it comes to NVDA… “acceleration cycles” are the key
From DTI   |   Ad
Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.
Use this link to see Nvidia Unchained right away!